ArticleAngiogenesis2017
CXCL10 suppression of hem- and lymph-angiogenesis in inflamed corneas through MMP13.
Article in Angiogenesis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Cardiac lymphatic dysfunction and repair in cardiovascular disease.Nature reviews. Cardiology · 2026Review
- Exploiting the CXCR3/CXCL10 axis overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in HNSCC.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- Aspergillus fumigatus promotes tumor angiogenesis via SLC7A11 on myeloid-derived suppressor cells.EMBO reports · 2025Article
- CXCL10-dependent epithelial-vascular cross-talk for endothelial activation following SARS-CoV-2 infection.Scientific reports · 2025Article
- Different Expression of Vascularization and Inflammatory Regulators in Cells Derived from Oral Mucosa and Limbus.Bioengineering (Basel, Switzerland) · 2025Article
- Intratumoral antigen-presenting cell activation by a nanovesicle for the concurrent tertiary lymphoid structure de novo neogenesis.Science advances · 2025Article
- New targets of nascent lymphatic vessels in ocular diseases.Frontiers in physiology · 2024Review
- Rubella virus infection in endothelial cells reduces angiogenesis via interferon beta-induced CXCL10.iScience · 2023Article
- Lymphangiogenesis Guidance Mechanisms and Therapeutic Implications in Pathological States of the Cornea.Cells · 2023Review
- Case report: JAK inhibition as promising treatment option of fatal RVCLS due toFrontiers in neurology · 2023Article
- Assessing the effects of aging on the renal endothelial cell landscape using single-cell RNA sequencing.Frontiers in genetics · 2023Article
- CXCR3 deletion aggravates corneal neovascularization in a corneal alkali-burn model.Experimental eye research · 2022Article
- PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p.Journal of experimental & clinical cancer research : CR · 2022Article
- The Role of Geranylgeraniol in Managing Bisphosphonate-Related Osteonecrosis of the Jaw.Frontiers in pharmacology · 2022Review
- Role of CXCL10 in Spinal Cord Injury.International journal of medical sciences · 2022Review
- Role of IL-36γ/IL-36R Signaling in Corneal Innate Defense Against Candida albicans Keratitis.Investigative ophthalmology & visual science · 2021Article
- CNTF Prevents Development of Outer Retinal Neovascularization Through Upregulation of CxCl10.Investigative ophthalmology & visual science · 2020Article
- Pharmacological Inhibition of Caspase-8 Suppresses Inflammation-Induced Angiogenesis in the Cornea.Biomolecules · 2020Article
- Effects of Retinal Transcription Regulation After GB20 Needling Treatment in Retina With Optic Neuritis.Frontiers in integrative neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
Abstract
Though not present in the normal adult cornea, both hem- and lymph-angiogenesis can be induced in this tissue after an inflammatory, infectious, or traumatic insult. We previously showed that the chemokine CXCL10 plays a key role in eradicating invading Candida (C.) albicans in C57BL6 mouse corneas. However, even after the clearance of pathogens, infection-induced inflammation and angiogenesis continue to progress in the cornea. The aim of this study is define the role of CXCL10 as a major angiostatic factor in modulating cornea angiogenesis in B6 mouse corneas under pathogenic conditions. We showed that epithelial expression of CXCL10, driven by AAV9 vector, suppressed both infection- and inflammation-induced hem and lymph angiogenesis, whereas the neutralization of CXCL10 as well as its receptor CXCR3 greatly promoted these processes. The inhibitory effect of CXCL10 was unrelated to its antimicrobial activity, but through the suppression of the expression of many angiogenic factors, including VEGFa and c, and MMP-13 in vivo. Inhibition of MMP13 but not TIMPs, attenuated suture-induced neovascularization but had no effects on CXCL10 expression. Strikingly, topical application of CXCL10 post-C. albicans infection effectively blocked both hem- and lymph-angiogenesis and preserved the integrity of sensory nerves in the cornea. Taken together, CXCL10 has strong inhibitory effects on neovascularization, whereas MMP13 is required for neovascularization in C. albicans-infected corneas and the local application of CXCL10 or MMP13 inhibitors, alone or as adjuvant therapy, may target hem- and lymph-angiogenesis in the inflamed corneas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.